At the last check on Friday, STAAR Surgical Company’s (NASDAQ:STAA) stock was up $1.5, moving up 3.62 percent to $43.13. The average number of shares traded per day over the past five days has been 867,703 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.51 fall in that time frame. In the last twenty days, the average volume was 812,976, while in the previous 50 days, it was 705,194.
Since last month, STAA stock retreated -19.31%. Shares of the company fell to $40.95 on 08/17/23, the lowest level in the past month. A 52-week high of $104.22 was reached on 02/02/23 after having rallying from a 52-week low of $40.95. Since the beginning of this year, STAA’s stock price has dropped by -11.14% or -$5.43, and marked a new high 12 times. However, the stock has declined by -58.61% since its 52-week high.
STAA stock investors should be aware that STAAR Surgical Company (STAA) stock had its last reported insider trading activity 11 days ago on Aug 07. WEISNER AIMEE S, the Director of the company, purchased of 2,000 shares for $48.72 on Aug 07. It resulted in a $97,440 investment by the insider. Holliday Keith sold 823 shares at an average price of $61.97 on Mar 17. The insider now owns 27,633 shares following the transaction. On Dec 29, 10% Owner BROADWOOD PARTNERS, L.P. bought 39,090 shares at $47.93 apiece. The transaction was valued at $1,873,431.
Valuation Metrics
Right now, STAAR Surgical Company (STAA) has a P/E ratio of about 85.76. The stock’s beta is 1.13. Besides these, the trailing price-to-sales (P/S) ratio of 6.91, the price-to-book (PB) ratio of 5.90.
Financial Health
In the three months ended June 29, STAAR Surgical Company’s quick ratio stood at 5.60, while its current ratio was 6.10, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 78.00% percent. In the year ended June 29, EBITDA margin amounted to 16.99%, whereas operating margins totaled 8.50%. Based on annual data, STAA earned $223.38 million in gross profit and brought in $284.39 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 11.10%. Return on equity (ROE) for the past 12 months was 7.40%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. STAA’s revenue rose 12.14% to $73.53 million during the quarter, while net income inched up to $92.31 million. While analysts expected STAAR Surgical Company to report $0.19 quarterly earnings, the actual figure was $0.4 per share, beating the consensus estimate by 110.50%. During the quarter, the company generated $9.21 million in EBITDA. The liabilities of STAAR Surgical Company were 86.95 million at the end of its most recent quarter ended June 29, and its total debt was $32.49 million. The value of shareholders’ equity is $48.5 million.
Technical Picture
This quick technical analysis looks at STAAR Surgical Company’s (STAA) price momentum. With a historical volatility rate of 37.35%, the RSI 9-day stood at 30.99% on 17 August.
With respect to its five-day moving average, the current STAAR Surgical Company price is down by -1.17% percent or -$0.51. At present, STAA shares trade -22.14% below its 20-day simple moving average and -32.12% percent below its 100-day simple moving average. However, the stock is currently trading approximately -16.50% below its SMA50 and -39.17% below its SMA200.
Stochastic coefficient K was 7.27% and Stochastic coefficient D was 4.43%, while ATR was 1.89. Given the Stochastic reading of 16.30% for the 14-day period, the RSI (14) reading has been calculated as 31.90%. As of today, the MACD Oscillator reading stands at -1.36, while the 14-day reading stands at -3.51.
Analyst Ratings
STAAR Surgical Company downgraded its rating on STAAR Surgical Company (NASDAQ: STAA) to a Hold in a note to investors on August 03, 2023. The analysts firm previously had a Buy rating on the stock.STAAR Surgical Company (STAA) has been rated Overweight by analysts. According to 0 brokerage firms, STAA is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate STAAR Surgical Company stock as buy, with 6 recommending it as overweight.
